Do analysts prefer AMPE or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, AMPE or CDT?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A

Is AMPE or CDT more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A CDT Equity N/A -72.25% -55.44%

Do analysts recommend VRPX or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, VRPX or CDT?

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A

Is VRPX or CDT more profitable?

CDT Equity's return on equity of -72.25% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% CDT Equity N/A -72.25% -55.44%

Do analysts recommend CDT or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CDT or PRPH more profitable?

CDT Equity has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. CDT Equity's return on equity of -72.25% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% ProPhase Labs -825.01% -482.05% -88.90%

Does the media prefer CDT or PRPH?

In the previous week, CDT Equity had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.34 beat CDT Equity's score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CDT or PTPI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CDT or PTPI more profitable?

CDT Equity's return on equity of -72.25% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Petros Pharmaceuticals N/A -78.22% -23.50%

Does the media prefer CDT or PTPI?

In the previous week, CDT Equity had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Petros Pharmaceuticals. CDT Equity's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Petros Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CDT or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, CDT or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is CDT or VINC more profitable?

CDT Equity's return on equity of -72.25% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Vincerx Pharma N/A -248.33% -132.73%

CDT Equity (CDT) Competitors

$0.91 -0.08 (-7.78%)

As of 02:49 PM Eastern

Compare

CDT vs. AMPE, VRPX, PRPH, PTPI, and VINC

Should you buy CDT Equity stock or one of its competitors? CDT Equity's main competitors and comparable companies include Ampio Pharmaceuticals (AMPE), Virpax Pharmaceuticals (VRPX), ProPhase Labs (PRPH), Petros Pharmaceuticals (PTPI), and Vincerx Pharma (VINC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CDT Equity compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Ampio Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
CDT Equity	N/A	-72.25%	-55.44%

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CDT Equity had 4 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled CDT Equity'saverage media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
CDT Equity	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Summary

Ampio Pharmaceuticals beats CDT Equity on 6 of the 10 factors compared between the two stocks.

How does CDT Equity compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, CDT Equity had 4 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled CDT Equity'saverage media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
CDT Equity	Neutral

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

Virpax Pharmaceuticals has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CDT Equity's return on equity of -72.25% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
CDT Equity	N/A	-72.25%	-55.44%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virpax Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CDT Equity beats Virpax Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does CDT Equity compare to ProPhase Labs?

CDT Equity (NASDAQ:CDT) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CDT Equity has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
ProPhase Labs	$5.06M	0.06	-$53.36M	-$2.25	N/A

CDT Equity has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. CDT Equity's return on equity of -72.25% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
ProPhase Labs	-825.01%	-482.05%	-88.90%

CDT Equity has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market.

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 7.3% of CDT Equity shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CDT Equity had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.34 beat CDT Equity's score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProPhase Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CDT Equity beats ProPhase Labs on 7 of the 12 factors compared between the two stocks.

How does CDT Equity compare to Petros Pharmaceuticals?

CDT Equity (NASDAQ:CDT) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Petros Pharmaceuticals has higher revenue and earnings than CDT Equity. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$0.36	N/A

CDT Equity's return on equity of -72.25% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

CDT Equity has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market.

In the previous week, CDT Equity had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Petros Pharmaceuticals. CDT Equity's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Petros Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 7.3% of CDT Equity shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Petros Pharmaceuticals beats CDT Equity on 7 of the 11 factors compared between the two stocks.

How does CDT Equity compare to Vincerx Pharma?

CDT Equity (NASDAQ:CDT) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

CDT Equity's return on equity of -72.25% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Vincerx Pharma	N/A	-248.33%	-132.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 7.3% of CDT Equity shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, CDT Equity had 4 more articles in the media than Vincerx Pharma. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Vincerx Pharma. CDT Equity's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
CDT Equity	Neutral
Vincerx Pharma	Neutral

Vincerx Pharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

CDT Equity has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Summary

CDT Equity beats Vincerx Pharma on 7 of the 10 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27K	$12.18B	$7.16B	$13.36B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	0.00	802.29	274.85	26.18
Price / Sales	N/A	755.34	614.67	93.04
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	N/A	10.65	11.25	6.40
Net Income	-$39.22M	$2.84B	$3.50B	$381.35M
7 Day Performance	-51.95%	-1.80%	-1.57%	-0.45%
1 Month Performance	-94.16%	-6.14%	-5.91%	-4.34%
1 Year Performance	-100.00%	-4.19%	7.98%	1.90%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.0578 of 5 stars	$0.91 -7.8%	N/A	-100.0%	$27K	N/A	N/A	4	High Trading Volume
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	6
VRPX Virpax Pharmaceuticals	N/A	$0.16 flat	N/A	+638.1%	$193K	N/A	N/A	2
PRPH ProPhase Labs	0.3032 of 5 stars	$0.01 -8.2%	N/A	-99.7%	$183K	$5.06M	N/A	130	Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.00 +15.0%	N/A	-84.6%	$143K	$5.11M	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. AMPE, VRPX, PRPH, PTPI, and VINC

How does CDT Equity compare to Ampio Pharmaceuticals?

Summary

How does CDT Equity compare to Virpax Pharmaceuticals?

Summary

How does CDT Equity compare to ProPhase Labs?

Summary

How does CDT Equity compare to Petros Pharmaceuticals?

Summary

How does CDT Equity compare to Vincerx Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. AMPE, VRPX, PRPH, PTPI, and VINC

How does CDT Equity compare to Ampio Pharmaceuticals?

Is AMPE or CDT more profitable?

Do institutionals and insiders have more ownership in AMPE or CDT?

Does the media refer more to AMPE or CDT?

Do analysts prefer AMPE or CDT?

Which has stronger earnings and valuation, AMPE or CDT?

Which has more risk and volatility, AMPE or CDT?

Summary

How does CDT Equity compare to Virpax Pharmaceuticals?

Does the media prefer VRPX or CDT?

Which has higher earnings and valuation, VRPX or CDT?

Which has more volatility & risk, VRPX or CDT?

Do institutionals & insiders hold more shares of VRPX or CDT?

Is VRPX or CDT more profitable?

Do analysts recommend VRPX or CDT?

Summary

How does CDT Equity compare to ProPhase Labs?

Do analysts recommend CDT or PRPH?

Which has stronger valuation & earnings, CDT or PRPH?

Is CDT or PRPH more profitable?

Which has more volatility and risk, CDT or PRPH?

Do institutionals and insiders believe in CDT or PRPH?

Does the media prefer CDT or PRPH?

Summary

How does CDT Equity compare to Petros Pharmaceuticals?

Which has better valuation and earnings, CDT or PTPI?

Is CDT or PTPI more profitable?

Which has more risk & volatility, CDT or PTPI?

Does the media prefer CDT or PTPI?

Do insiders and institutionals believe in CDT or PTPI?

Do analysts prefer CDT or PTPI?

Summary

How does CDT Equity compare to Vincerx Pharma?

Is CDT or VINC more profitable?

Do analysts prefer CDT or VINC?

Do institutionals and insiders hold more shares of CDT or VINC?

Does the media favor CDT or VINC?

Which has preferable earnings and valuation, CDT or VINC?

Which has more risk and volatility, CDT or VINC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools